Bio News

SK Biopharm has signed a licensing agreement with First Bio Therapeutics to secure global exclusive development and commercialization rights for a disease-modifying therapy (DMT) candidate for Parkinson disease. The total value of the agreement is approximately 430.8 billion won at most, and SK Biopharm also made a separate strategic equity investment worth 3 billion won.
SK Biopharm plans to consider follow-up development for an investigational new drug (IND) application based on future research results.

BIOBOOK TEAM
biobookmedia@biobook.co.krAsahi Kasei Wins FDA Approval for New Herpes Drug Hovlpri for Immunocompromised Adults
Mirum’s Livmarli succeeds in phase 3 trial, company seeks expanded indication for rare liver disease
Roche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count